Topic

Articles

Survey responses indicate that bio/pharma faces tariff-driven rising costs and supply strain, with firms aiming to boost compliance and diversification and seeking stable trade and R&D support.

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.

Survey: Impacts of Tariffs and Trade Policy on the Bio/pharmaceutical Industry

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

Agentic AI Growth Predicted, but More Than Half of Pharma Still Resisting Change: Report

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Videos

In an interview with Pharmaceutical Technology®, Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.

Industry Outlook 2025: Continuing Innovation 

Feliza Mirasol is the science editor for 

Industry 4.0 is driving adoption in the pharma industry for smart equipment 
and tools that will advance manufacturing.

Accelerating Adoption of Smart Tools to Advance Manufacturing 

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's  IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.

TrakCel’s OCELLOS Platform Selected to Support Treatment Management of Five Upcoming Cell Therapy Products

Chris Stumpf is director of Drug Discovery Informatics Solutions, Revvity Signals.

Capturing and curating R&D data are crucial to realizing the full value of advanced analytics.

Untethered Data: Unifying and Contextualizing Drug Discovery Data

With DKK 600 million (US$87.4 million) in funding from the Novo Nordisk Foundation, the new supercomputer offers the potential to accelerate innovation in drug discovery.

Denmark’s First AI Supercomputer for Drug Discovery Now Operational Under Novo Nordisk Foundation Commitment

Collecting and curating R&D data are increasingly crucial tasks for achieving the full benefits of advanced analytics. 

Unifying and Contextualizing Drug Discovery Data

The new meeting program will create a dialogue around AI and be administered through CDER’s Emerging Drug Safety Technology Program.

Data and Artificial Intelligence